1-20 of 44021
Sort by
Journal
Issue cover
A leading international journal in antimicrobial research, publishing original articles on the laboratory aspects and clinical use of antimicrobials. The official journal of the British Society for Antimicrobial Chemotherapy.
Journal
Issue cover
JAC-Antimicrobial Resistance is a new fully open access journal from the British Society for Antimicrobial Chemotherapy. The journal publishes academic content, as well as commentaries on stewardship resources.
Journal Article
Stella Babich and others
JAC-Antimicrobial Resistance, Volume 7, Issue 3, June 2025, dlaf066, https://doi.org/10.1093/jacamr/dlaf066
Published: 05 May 2025
Image
Published: 05 May 2025
Figure 1. Timeline of the clinical case, illustrating key events and antibiotic therapy. Css: steady-state concentration; TDM: therapeutic drug monitoring. After an initial course of 10 days of ceftazidime/avibactam plus aztreonam, our patient relapsed after nearly 11 months and he was treated with cefider
Image
Published: 02 May 2025
Figure 2. PI minor drug resistance mutations among adolescents and youths ( n  = 16).
Image
Published: 02 May 2025
Figure 3. NRTI drug resistance mutations among adolescents and youths ( n  = 51).
Journal Article
Jacob T Dumbleton and others
JAC-Antimicrobial Resistance, Volume 7, Issue 3, June 2025, dlaf068, https://doi.org/10.1093/jacamr/dlaf068
Published: 02 May 2025
Image
Published: 02 May 2025
Figure 1. Static time–kill results of A. baumannii isolates versus combination β-lactam therapies with and without polymyxin B. Observed bacterial concentrations (cfu/mL) of A. baumannii isolates AR-0033 (A1–A5) and AR-0083 (B1–B5) over 24 h as mean (dots) and standard deviation (bars) from replicates. Pl
Image
Published: 02 May 2025
Figure 1. PI major drug resistance mutations among adolescents and youths ( n  = 76).
Image
Published: 02 May 2025
Figure 4. Genotypic susceptibility levels of the PI drugs among adolescents and youths with virological failure. ATV/r, ritonavir boosted atazanavir; DRV/r, boosted Darunavir with ritonavir; LPV/r, boosted Lopinavir with ritonavir.
Image
Published: 02 May 2025
Figure 2. Hill-type function modelled over observed log ratio area. A Hill-type function modelled over recorded changes in growth-normalized log ratio area due to polymyxin B concentrations to determine I max and IC 50 . Aztreonam (ATM) concentrations are in the aztreonam/ceftazidime/avibactam combination
Image
Published: 02 May 2025
Figure 3. Percentage of time above estimated IC 50 values of aztreonam. Six simulated dosing regimens over the course of 144 h to determine the percentage of time a simulated subject would have a f C ss,avg above the estimated aztreonam IC 50 value. Aztreonam was simulated as a maintenance dose of 500 mg,
Journal Article
Joan Rugemalila and others
Journal of Antimicrobial Chemotherapy, dkaf125, https://doi.org/10.1093/jac/dkaf125
Published: 02 May 2025
Image
Published: 30 April 2025
Figure 4. Probability of PK/PD target attainment for rezafungin 400 mg against C. auris using CLSI methodology. 79   f AUC 0–168 h , free-drug area under the plasma concentration–time curve from 0 to 168 h; cfu, colony-forming units; CLSI, Clinical and Laboratory Standards Institute; MIC, minimum inhibit
Journal Article
Hideki Hashimoto and others
JAC-Antimicrobial Resistance, Volume 7, Issue 3, June 2025, dlaf062, https://doi.org/10.1093/jacamr/dlaf062
Published: 30 April 2025
Journal Article
Davide Mangioni and others
JAC-Antimicrobial Resistance, Volume 7, Issue 3, June 2025, dlaf067, https://doi.org/10.1093/jacamr/dlaf067
Published: 30 April 2025
Image
Published: 30 April 2025
Figure 3. Growth curves for C. parapsilosis parental and mutant strains. (a) Parental strains: CpATCC 22019, CpL and CpM. (b) Heterozygous clones: CpALPHA-4 and CpM-19. (c) Homozygous clones: CpALPHA-24, CpL-6, CpM-WOLV and CpM-PHOE. Error bars express SD of the mean.
Journal Article
Jeffrey B Locke and others
Journal of Antimicrobial Chemotherapy, dkaf124, https://doi.org/10.1093/jac/dkaf124
Published: 30 April 2025
Image
Published: 30 April 2025
Figure 1. ( A ) Clinical cases of C. auris reported in the USA (2023; n  = 4514); 16 ( B ) Case reports of C. auris infection or carriage within countries included in the EU or EEA, excluding the UK (2013–21; n  = 1812). 12 AK, Alaska; AL, Alabama; AR, Arkansas; AZ, Arizona; CA, California; CO, Co
Image
Published: 30 April 2025
Figure 2. Toxicity and survival curves in M. mycetomatis -infected G. mellonella larvae treated with ibrexafungerp and micafungin. (a) Ibrexafungerp (IBX) was evaluated for toxicity in G. mellonella larvae. Three concentrations, 8 (dark red with dashed line), 2 (bright red with dashed line) and 0.5 (ligh